Zobrazeno 1 - 10
of 29
pro vyhledávání: '"Mary K, Klein"'
Autor:
Abbey R. Sadowski, Heather L. Gardner, Antonella Borgatti, Heather Wilson, David M. Vail, Joshua Lachowicz, Christina Manley, Avenelle Turner, Mary K. Klein, Angharad Waite, Alexandra Sahora, Cheryl A. London
Publikováno v:
BMC Veterinary Research, Vol 14, Iss 1, Pp 1-7 (2018)
Abstract Background Chemotherapeutic options for the treatment of canine lymphoma have not changed in several decades necessitating the identification of new therapeutics to improve patient outcome. KPT-335 (verdinexor) is a novel orally bioavailable
Externí odkaz:
https://doaj.org/article/5970ac9c08524ac99e1ae4efc81b1bbf
Autor:
Gina M. Michels, Guy N. Mauldin, Guillermo C. Couto, Philip J. Bergman, John G. Hintermeister, Mary K. Klein, Kathy L. Mitchener, Carolyn J. Henry, Mona P. Rosenberg, Anthony W. Rusk, Joseph F. Boucher, Stacey L. Wood-Follis, Phyllis B. Malpas, Cheryl A. London
CCR Translation for the Article from Multi-center, Placebo-controlled, Double-blind, Randomized Study of Oral Toceranib Phosphate (SU11654), a Receptor Tyrosine Kinase Inhibitor, for the Treatment of Dogs with Recurrent (Either Local or Distant) Mast
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0fef82286050475b661a767bed1f4a4b
https://doi.org/10.1158/1078-0432.22440501.v1
https://doi.org/10.1158/1078-0432.22440501.v1
Autor:
Gina M. Michels, Guy N. Mauldin, Guillermo C. Couto, Philip J. Bergman, John G. Hintermeister, Mary K. Klein, Kathy L. Mitchener, Carolyn J. Henry, Mona P. Rosenberg, Anthony W. Rusk, Joseph F. Boucher, Stacey L. Wood-Follis, Phyllis B. Malpas, Cheryl A. London
Purpose: The purpose of this study was to determine the objective response rate (ORR) following treatment of canine mast cell tumors (MCT) with toceranib phosphate (Palladia, SU11654), a kinase inhibitor with both antitumor and antiangiogenic activit
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0151bd6253374e838a23d3be72e6de4b
https://doi.org/10.1158/1078-0432.c.6517818
https://doi.org/10.1158/1078-0432.c.6517818
Autor:
Gina M. Michels, Guy N. Mauldin, Guillermo C. Couto, Philip J. Bergman, John G. Hintermeister, Mary K. Klein, Kathy L. Mitchener, Carolyn J. Henry, Mona P. Rosenberg, Anthony W. Rusk, Joseph F. Boucher, Stacey L. Wood-Follis, Phyllis B. Malpas, Cheryl A. London
Supplementary Data from Multi-center, Placebo-controlled, Double-blind, Randomized Study of Oral Toceranib Phosphate (SU11654), a Receptor Tyrosine Kinase Inhibitor, for the Treatment of Dogs with Recurrent (Either Local or Distant) Mast Cell Tumor F
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::aaeb1b053da01710fb8983faaa9a16d9
https://doi.org/10.1158/1078-0432.22440498.v1
https://doi.org/10.1158/1078-0432.22440498.v1
Autor:
Cheryl A London, Heather L Gardner, Tamra Mathie, Nicole Stingle, Roberta Portela, Michael L Pennell, Craig A Clifford, Mona P Rosenberg, David M Vail, Laurel E Williams, Kim L Cronin, Heather Wilson-Robles, Antonella Borgatti, Carolyn J Henry, Dennis B Bailey, Jennifer Locke, Nicole C Northrup, Martin Crawford-Jakubiak, Virginia L Gill, Mary K Klein, David M Ruslander, Doug H Thamm, Brenda Phillips, Gerald Post
Publikováno v:
PLoS ONE, Vol 10, Iss 4, p e0124889 (2015)
We hypothesized that the addition of toceranib to metronomic cyclophosphamide/piroxicam therapy would significantly improve disease-free interval (DFI) and overall survival (OS) in dogs with appendicular osteosarcoma (OSA) following amputation and ca
Externí odkaz:
https://doaj.org/article/a53bde96293544248c55b1e08df0a365
Autor:
Corey F. Saba, Lauren Smith, Mary K. Klein, Janean Fidel, Siobhan Haney, Eric M. Green, John Farrelly, William R. Brawner, Keijiro Shiomitsu, Tracey LaDue, Jayme Looper, Michelle Turek, Deborah Prescott, Tara Jean Ehling
Publikováno v:
Veterinary and comparative oncologyREFERENCES. 20(1)
Radiation is the standard of care for dogs with nasal tumors. The addition of another therapy that could improve outcome without increasing toxicity is attractive. Medical therapy that could offer better outcome than maximally tolerated dose chemothe
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7c20e3bad2b28fbbfac031233994349c
https://pubmed.ncbi.nlm.nih.gov/34655275
https://pubmed.ncbi.nlm.nih.gov/34655275
Autor:
David M. Vail, Mary K. Klein, Heather L. Wilson, Antonella Borgatti, Christina Manley, Alexandra Sahora, Avenelle I. Turner, Heather L. Gardner, Joshua Lachowicz, Angharad Waite, Cheryl A. London, Abbey R. Sadowski
Publikováno v:
BMC Veterinary Research, Vol 14, Iss 1, Pp 1-7 (2018)
BMC Veterinary Research
BMC Veterinary Research
Background Chemotherapeutic options for the treatment of canine lymphoma have not changed in several decades necessitating the identification of new therapeutics to improve patient outcome. KPT-335 (verdinexor) is a novel orally bioavailable selectiv
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bd1f6fb49e049a7be40030a8b35a59cb
http://link.springer.com/article/10.1186/s12917-018-1587-9
http://link.springer.com/article/10.1186/s12917-018-1587-9
Autor:
D.A. Ruslander, Timothy M. Fan, R.S. Elmslie, Brenda Phillips, David M. Vail, G. S. Post, Mary K. Klein, Sandra M. Axiak-Bechtel, Douglas H. Thamm
Publikováno v:
Journal of Veterinary Internal Medicine
Background Standard of care treatment for multicentric lymphoma in dogs remains doxorubicin (DOX)-based combination chemotherapy, but owners may hesitate to commit the time and financial resources to complete such a protocol, typically requiring 12
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::70898497f94bbcc2f2cc70b7adfcfe99
http://europepmc.org/articles/PMC5435064
http://europepmc.org/articles/PMC5435064
Autor:
Steven Susaneck, Monika K. Jankowski, Paul R. Hess, Mary K. Klein, Jedd D. Wolchok, Philip J. Bergman, Ilene D. Kurzman, Pamela D Jones, Deborah A. Grosenbaugh, Maribeth H. Johnson, A. Timothy Leard, Nicole F. Leibman, Karri Meleo
Publikováno v:
American Journal of Veterinary Research. 72:1631-1638
Objective—To evaluate the safety and efficacy of a vaccine containing plasmid DNA with an insert encoding human tyrosinase (ie, huTyr vaccine) as adjunctive treatment for oral malignant melanoma (MM) in dogs. Animals—111 dogs (58 prospectively en
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::84b3f7fcb8a54738fca9fafcc92d6e5c
https://doi.org/10.2460/ajvr.72.12.1631
https://doi.org/10.2460/ajvr.72.12.1631
Publikováno v:
Journal of the American Veterinary Medical Association. 237:1052-1055
Objective—To determine the response rate after administration of a single dose of doxorubicin in dogs with B-cell or T-cell multicentric or thymic lymphoma. Design—Retrospective case series. Animals—41 client-owned dogs with lymphoma. Procedure
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::44ea2efe8e5f21715f432f7afaa80dc0
https://doi.org/10.2460/javma.237.9.1052
https://doi.org/10.2460/javma.237.9.1052